Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma.

MLA

Zheng, Wei, et al. “Poly(Lactic Acid Hydroxyacetic Acid)-Poly(Ethylene Glycol)-Modified Ginsenoside Rg3 Nanomedicine Enhances Anti-Tumor Effect in Hepatocellular Carcinoma.” Drug Development & Industrial Pharmacy, vol. 50, no. 8, Aug. 2024, pp. 763–75. EBSCOhost, https://doi.org/10.1080/03639045.2024.2402769.

APA

Zheng, W., Huang, Y., Wu, Q., Cheng, P., Song, Y., Wang, B., Huang, Q., & Hu, S. (2024). Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma. Drug Development & Industrial Pharmacy, 50(8), 763–775. https://doi.org/10.1080/03639045.2024.2402769

Chicago

Zheng, Wei, Yuqiao Huang, Qiong Wu, Pu Cheng, Yujun Song, Ben Wang, Qi Huang, and Shen Hu. 2024. “Poly(Lactic Acid Hydroxyacetic Acid)-Poly(Ethylene Glycol)-Modified Ginsenoside Rg3 Nanomedicine Enhances Anti-Tumor Effect in Hepatocellular Carcinoma.” Drug Development & Industrial Pharmacy 50 (8): 763–75. doi:10.1080/03639045.2024.2402769.